The company recently hit significant roadblocks with its BTK inhibitor, but there are plenty of fish in the sea for the drug ...

Gilenya and Tascenso ODT are approved to treat relapsing forms of multiple sclerosis (MS) in adults. Gilenya and Tascenso ODT ...

Brenig has launched an early Phase 1 trial to evaluate BT-409, its experimental small molecule therapy, in healthy volunteers ...

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...

The Elliot's Neurological Specialties clinic combines medical treatments to slow MS progression with holistic approaches to ...

Cladribine, a nucleotide (deoxyadenosine) analogue, inhibits deoxyribonucleic acid (DNA) synthesis in proliferating lymphocytes, causing DNA damage and depleting their number by apoptosis and ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. March is Multiple Sclerosis Awareness Month, a time to ...

VANCOUVER, BC / ACCESS Newswire / January 21, 2026 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTCQB:BNXTF)(FSE:BXT) is pleased to report final results from a preclinical pig study ...

Pre-clinical studies using a small molecule drug have shown promise as a potential new treatment for multiple sclerosis (MS). CAMH-led pre-clinical studies using a small molecule drug have shown ...

Find Therapeutics secured CA$10 million in funding to continue advancing tasronetide, its treatment to restore damaged myelin ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

In India, 2L+ people have MS, but lack standard care. Experts at a Bengaluru event urged for better data, insurance, and ...